Views on artificial intelligence (AI) assisted clinical trials

Arthi Balasundaram1*, C. Stalin2 & Mohan Krishna Ghanta3

1Biohymns Innovations Pte ltd, Singapore, Email Id- rtms86@yahoo.com; 2Pharmacovigilance Associate, Pharmacovigilance Programme of India (PVPI), Indian Pharmacopoeia Commission, Ghaziabad, India-201002, Email Id- stalinmpharm@gmail.com; 3Department of Pharmacology, MVJ Medical College and Research Hospital, Hoskote, Bangalore-562114, Karnataka, India, Email id-gmkchowdary81@yahoo.co.in. *Corresponding author - Dr. Arthi Balasundaram, Biohymns Innovations Pte ltd, Singapore. Email Id: rtms86@yahoo.com, arthi@biohymns.com

Received May 25, 2021; Revised May 30, 2021; Accepted May 30, 2021, Published June 30, 2021

DOI: 10.6026/97320630017616

Declaration on Publication Ethics:
The authors state that they adhere to COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any misleading information to the publisher regarding this article.

Author responsibility:
The authors are responsible for the content of this article.

Declaration on official E-mail:
The corresponding author declares that an official e-mail from the institution is not available for all authors.

Abstract
It is of interest to document the views of medical professionals on the application of artificial intelligence (using known data for the prediction of unknown events) in clinical trials using a web survey with a structured questionnaire from 377 subjects. The questionnaire contained 17 statements which were categorised into awareness (1,2 statements), perception (3-10 statements) and opinion (11-17 statements). The data obtained was compared between the subjects using two tailed Fisher’s exact test with p-value <0.05 for data significance analysis. Data shows that majority of professionals have positive views on the application of artificial intelligence in clinical trials. This will accelerate the drug evaluation process. However, the use of emerging tools such as AI will not replace human subjects in this context.

Keywords: Artificial intelligence, questionnaire study, clinical trials.

Background
New drugs require more than 10 years to reach the market [1]. Hence, investment in drug design, research, development and formulation comes with high risk for pharma companies [2, 3]. Therefore, the use of artificial intelligence help clinicians and researcher to identify specific targets in this context [4].
Materials and Methods:
This study was conducted by BioHymns Innovations Pte. Ltd, Singapore, during Dec 2019 to May 2020 in Tamil Nadu, India. The sample size was measured using the Raosoft online calculator (Raosoft) and included 377 subjects. Medical doctors, who are involved or have been involved in clinical trials as investigator or co-investigator and medical Doctors who are interested in participating in this online survey were included in the study. Medical doctors who are not involved or have not been involved in clinical trials, non-medical doctors and medical doctors not interested in participating this online survey were excluded from the study.

Study procedure:
This was a questionnaire-based study. Regarding questionnaire validity and reliability, a structured questionnaire was developed after a thorough literature review, which was conducted initially by the chief investigator and research papers were shortlisted for further discussion among the research team. All the views, thoughts and concerns on the proposed study were taken into consideration during the design phase. An initial draft of the questionnaire was designed after the research team had reviewed all the selected papers comprehensively. Individual survey items were reviewed by a group of medical professionals and consensus were reached regarding the clarity and importance of each item. The validation process was further expanded by piloting the questionnaire with four experienced doctors who meet the eligibility criteria and are not aware of this study. There was voluntary participation by the physicians. The questionnaire was framed in English. The questionnaire comprised 17 statements which were sectioned into 3 events like awareness (1,2 statements), perception (3-10 statements) and opinion (11-17 statements). After obtaining ethics committee approval VISTAS-SPS/IEC/VIII/2019/04, the questionnaire was shared to professionals involved in clinical trials using survey Google forms.

Statistical analysis:
An anonymous questionnaire was shared through Google forms to all participants. Basic statistics for the responses was done and represented as total number and percent. The data obtained was compared between the specialities using two tailed Fisher’s exact test. P-value <0.05 was taken as significant.

Results:
This study included 377 participants comprising resident doctors (N= 143), doctors working as clinical research associates (N= 12), paediatricians (N= 7), general physicians (N= 47), pharmacologists (N= 161), and clinical trial physicians (N= 7). The questionnaire consisting 17 statements have been categorized into 3 types as for awareness, perception and opinion. The statements in the questionnaire were enlisted in Table 1. The response rate towards the questionnaire statements was 100%.

Responses against questionnaire statements
The consolidated responses were tabulated in Table 1. To describe the responses in general, majority (83.5 % & 65.5%) of the participants were aware of the AI based health care delivery and clinical trials. Most of the participants identified the potentiality of AI in, clinical trial processes, time saving or accelerating drug development, cost-effectiveness, and handling vast data. The AI based clinical trials was supported by large number of participants, but some has suggested that AI cannot substitute human intelligence and also, might raise ethical and legal concerns.

Awareness
Statements 1 and 2 were categorised for analysis of awareness in this study. The responses were analysed as per the category of speciality. 220 positive responses out of 286 towards awareness were obtained from resident doctors. 16/24, 9/14, 66/94, 242/322, and 9/14 positive responses were obtained from clinical research associates, paediatricians, general physicians, pharmacologists, and clinical trial physicians respectively (Figure 1).

Perception
Statements from 3 to 10 comprised analysis for perception. 1012/1144, 75/96, 48/56, 319/376, 111/1288, and 47/56 positive responses revealed the perception or recognition of the scope of AI in clinical trials by residents, clinical research associates, paediatricians, general physicians, pharmacologists, and clinical trial physicians respectively (Figure 1).

Opinion
Most of the specialists’ responses (residents- 805/1001, clinical research associates- 66/84, paediatricians- 42/49, general physicians- 239/329, pharmacologists- 847/1127, and clinical trial physicians- 43/49) have supported the AI in clinical trials [Figure 1]. But in comparison, the pharmacologists and general physicians’ responses to opinion section showed significant difference (P value-0.004 and 0.004 respectively) to other groups (Figure 2).
Figure 1: Questionnaire statement wise specialists’ responses for AI based clinical trials. Y-positive response, N- negative response, %-percentage of response.
Figure 2: Awareness, perception and opinion responses of medical specialists for AI based clinical trials. CRA- Clinical Research Associate, PED- Paediatrician, GEN P- General Physician, PHARM- Pharmacologists, CTP- Clinical trial Physicians. *- p value obtained with two tailed Fisher’s exact test.

Table 1: Questionnaire statements and consolidated responses (Total responses N - 377), n - number of responses obtained.

| S.No | Statements                                                                 | YES n (%) | NO n (%) |
|------|----------------------------------------------------------------------------|-----------|----------|
| 1    | Are you aware about artificial intelligence (AI) application in healthcare? | 315 (83.55) | 62 (16.44) |
| 2    | Are you aware that artificial intelligence algorithms can be used in clinical trials process? | 247 (65.51) | 130 (34.48) |
| 3    | Do you think that Artificial intelligence has the potential to disrupt every stage of the clinical trials process? | 278 (73.74) | 99 (26.25) |
| 4    | Do you think the use of the Electronic Medical Record (EMR) has the potential to reduce patient recruitment time? | 370 (98.14) | 7 (1.85) |
| 5    | Do you think AI technology can dramatically shorten the time of life-saving drugs to enter into the market? | 350 (92.83) | 27 (7.16) |
| 6    | Do you think AI technology can streamline the clinical trial processes and reduce drug development time? | 358 (94.96) | 19 (5.03) |
| 7    | Do you think AI can enable sponsors to optimize clinical trials and accelerate new product development? | 352 (93.36) | 25 (6.63) |
| 8    | Do you think AI technology can be a very reliable and cost-effective recruiting tool for clinical trials? | 282 (74.80) | 95 (25.19) |
| 9    | Do you think AI, machine learning and deep learning techniques can be useful in managing vast volumes of clinical research data? | 343 (90.98) | 34 (9.01) |
| 10   | Do you think AI, machine learning and deep learning techniques can comparatively reduce the dropout rate in clinical trials? | 288 (76.39) | 89 (23.60) |
| 11   | AI-driven protocol designs powered by AI algorithms and deep learning techniques can make clinical trials more intelligent? | 300 (79.57) | 77 (20.42) |
| 12   | AI, machine learning and deep learning techniques can Increase Clinical Trial Success Rates? | 310 (82.22) | 67 (17.77) |
| 13   | Artificial intelligence could improve key parts of the clinical trial process, including selection and recruitment and patient monitoring. | 335 (88.85) | 42 (11.14) |
| 14   | Do you think real time data capturing with the aid of wearables will enable better patient recruitment for clinical trials? | 331 (87.79) | 46 (12.20) |
| 15   | Will you be interested to use AI based interface for your clinical trial process such as patient recruitment? | 315 (83.55) | 62 (16.44) |
| 16   | AI can substitute human intelligence and provide more accurate results when applied in healthcare domain? | 118 (31.29) | 259 (68.70) |
| 17   | AI in clinical trials may cause ethical & legal concerns | 333 (88.32) | 44 (11.67) |
Discussion:
It is of interest to document the awareness, perception and opinion on AI based clinical trials amongst medical professionals using an online questionnaire survey. The study results statistically revealed comparable positive responses of awareness, perception and opinion between the specialities or specialists of medical profession. The pharmacologists and general physicians’ responses in comparison to other specialities for opinion showed significant difference (P value-0.004 and 0.004 respectively) to other groups. This may be due to the responses to statement 16 where they suggested that AI cannot replace human intelligence. Majority of the medical specialities’ responses have shown that AI can cause ethical and legal concerns in clinical trials. Most of the specialists (88.85%) have supporting opinion towards AI based clinical trials, for accelerating the clinical trial process, aiding in patient recruitment and patient monitoring with suggestion of its usage (83.55%). These processes in clinical trials are very important and may decide the clinical trial outcome. It is known that these processes like substandard patient recruitment and withholding, ineffective patient monitoring contribute to the failure of clinical trial or raise of trial costs [5]. The participants’ responses in this study state that AI cannot be a substitute of human intelligence. This is supported by other studies [6, 7, 8]. Conversely, another study suggested that replacement of doctors might happen based upon the rapid scientific advancements. IBM’s Watson database was developed comprising vast information of publications and medical records which may assist in accurate diagnosis and treatments. This database also has genome information which may aid in personalised medicine [9, 10, 11]. Majority of participants (82.2%) suggested that AI may increase the success rates of clinical trials. Several difficulties are confronted in use of AI for convalescing outputs in drug development and healthcare. Perception of the risks and difficulties engrossed in its use and operation is dominant for improvement of responsive directives in this area [12].

Conclusion:
Data shows that the medical professionals have awareness, perception and opinion on AI based clinical trials for further consideration in this domain.

Acknowledgements:
We would like to thank Dr. Punnagai, Professor & HOD department of Pharmacology, SRIHER. We also thank the participants who contributed towards this survey.

References: Give PMID
[1] DiMasi JA et al. Clin Pharmacol Ther. 2010 87:272.
[2] DiMasi J.A et al. J Health Econ. 2016 47:20.
[3] Paul S.M et al. Nat Rev Drug Discov. 2010 9:203.
[4] Liyanage H et al. Yearb Med Inform. 2019 28:41.
[5] V.S. Nayak et al. Int’l J. Clinical Trials. 2016 3:187.
[6] Chockley K et al. J Am Coll Radiol. 2016 13:1415.
[7] Lusted L.B. Radiology, 1960 74:178.
[8] Schwartz WB. N Engl J Med. 1970 283:1257.
[9] Trivedi H et al. J Digit Imaging. 2018 31:245.
[10] Bakkar N et al. Acta Neuropathol. 2018 135:227.
[11] Malin JL. J Oncol Pract. 2013 9:155.
[12] Sahoo N et al. Fitoterapia. 2010 81:462.
Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article for FREE of cost without open access charges. Comments should be concise, coherent and critical in less than 1000 words.
